Core Viewpoint - DBV Technologies has successfully raised €166.7 million through the full exercise of ABSA and BS Warrants, which will support the launch of the VIASKIN® Peanut patch for children aged 4 to 7 years in the U.S., pending approval [1][11]. Financing Details - The financing involved the issuance of 34,090,004 ABSA Warrants and 71,005,656 BS Warrants, leading to the issuance of 59,657,507 new ordinary shares and up to 124,259,898 pre-funded warrants [1][5]. - The exercise price for the ABSA Warrants was €1.5939, while the BS Warrants had an exercise price of €1.5764 [1][6]. Use of Proceeds - The gross proceeds from the exercise will be utilized for working capital, general corporate purposes, and to finance the preparation and submission of a potential Biologics License Application (BLA) for the VIASKIN® Peanut patch [10][11]. - The total financing, including potential exercises of outstanding warrants, is estimated to reach approximately €284.5 million [10]. Shareholder Impact - The issuance of new shares will dilute existing shareholders' equity, with ownership interest for a shareholder holding 1.00% of the Company's share capital decreasing to 0.78% on a non-diluted basis after the issuance [15]. - The shareholding structure will change post-issuance, with Baker Brothers Investments retaining 8.64% and Janus Henderson acquiring 7.54% of the diluted share capital [17]. Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology [19]. - The company is headquartered in Châtillon, France, with operations in North America [20].

Core Insights - DBV Technologies will participate in the ACAAI 2025 Annual Scientific Meeting from November 6 to 10 in Orlando, Florida [1] - The company will host a Product Theater discussing the benefits of early intervention in food allergy management [2][3] - A planned Phase 2 clinical study will assess the efficacy and safety of the VIASKIN® Peanut patch for peanut-allergic infants aged 6 to 12 months [2][4] Product Theater Details - Dr. Gideon Lack will lead discussions on proactive food allergy management and the potential of the VIASKIN® Peanut patch [3] - The study aims to determine if earlier intervention can facilitate ad lib peanut consumption in young children [3] - Dr. Matthew Greenhawt will present end-of-study results from the EPITOPE study during the meeting [3][8] Company Commitment - DBV Technologies emphasizes its commitment to the younger patient population in the food allergy community [4] - The company anticipates a potential BLA filing for the VIASKIN® Peanut patch for toddlers aged 1 to 3 years in the second half of next year [4] - DBV is focused on developing treatment options for food allergies using its proprietary VIASKIN® patch technology [9] Event Participation - DBV will exhibit at booth 711 and sponsor the 34th Annual FIT Bowl™, a competition testing knowledge in allergy, asthma, and immunology [6] - The competition is scheduled for November 8, 2025 [6] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [10] - The company is dedicated to transforming the care of individuals with food allergies through innovative therapies [9]

Core Viewpoint - DBV Technologies announced the resignation of Daniel Soland from its Board of Directors, effective immediately, and expressed gratitude for his contributions since 2015 [1][2]. Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3]. - The company is investigating its proprietary VIASKIN® patch technology, which aims to address food allergies through epicutaneous immunotherapy (EPIT) [3]. - The VIASKIN® patch is designed to introduce microgram amounts of biologically active compounds to the immune system via intact skin, aiming to modify the underlying allergy and desensitize the immune system [3]. Current Operations - DBV Technologies is conducting ongoing clinical trials of the VIASKIN Peanut patch for peanut allergic toddlers (ages 1 to 3) and children (ages 4 to 7) [3]. - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [4]. - The ordinary shares of DBV Technologies are traded on segment B of Euronext Paris, and its American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market [4].